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Abstract
This article is a transcription of an electronic symposium sponsored by
the Brazilian Society of Neuroscience and Behavior (SBNeC). Invited
researchers from the European Union, North America and Brazil
discussed two issues on anxiety, namely whether panic is a very
intense anxiety or something else, and what aspects of clinical anxiety
are reproduced by animal models. Concerning the first issue, most
participants agreed that generalized anxiety and panic disorder are
different on the basis of clinical manifestations, drug response and
animal models. Also, underlying brain structures, neurotransmitter
modulation and hormonal changes seem to involve important differ-
ences. It is also common knowledge that existing animal models
generate different types of fear/anxiety. A challenge for future re-
search is to establish a good correlation between animal models and
nosological classification.
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The last decade witnessed major advances
in the understanding of the neuroanatomical
and neurohumoral basis of anxiety. Also,
pharmacological and psychotherapeutic treat-
ment of anxiety disorders became more ef-
fective. Yet, some crucial issues concerning
the neurobiological substrate of anxiety dis-
orders remain open to debate. Among such
questions two were selected for the follow-
ing discussion, namely whether panic is a
very intense anxiety or something else, and
what aspects of clinical anxiety are repro-
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duced by animal models. The present article
was based on the transcription of an elec-
tronic symposium sponsored by the Brazil-
ian Society of Neuroscience and Behavior
(SBNeC) held on April 26, 2000 at a chat site
provided by the Conselho Nacional de De-
senvolvimento Científico e Tecnológico
(CNPq).
Frederico Graeff: Let us start with the
first question: Is panic a big anxiety or is it
something else?
Luiz Carlos Schenberg: Let me try. Con-
cerning the question about anxiety and panic,
maybe panic is a sudden and intense wave of
anxiety; however, if so, this makes a big
difference in terms of clinical, physiological
and pharmacological aspects. Why such a
big responsiveness?
Padua Carobrez: Recurrent panic suf-
ferers can learn how to avoid places based
on a general context cue, but do they learn
how to cope with this in the future? They
sure avoid places but the inability to learn
during the attack does not allow them to
challenge or face the situation in the future.
Sheila Handley: Professor Graeff has
posed an interesting question. I think the
answer to Is fear a big anxiety? depends on
what you include. Emotions are notoriously
difficult to translate into words, and it would
be very difficult to argue the question one
way or the other on the basis of the emotion
alone. But the picture may be different if
inputs and outputs are included too. Back in
1962, Taylor (1) showed that the perceptual
and stimulus properties of objects in the
environment depend strongly on our cumu-
lative experience of how we can interact
with them. On this basis, one could argue
that the stimulus properties giving rise to an
emotion are an essential component of the
emotional experience. The stimulus proper-
ties of cues to anxiety and to panic are argu-
ably different and roughly comparable to
distal and proximal cues, respectively (2).
Behavioral and autonomic output and, cru-
cially, the feedback we receive from these,
may also be integral components. Yes -
shades of James-Lange - and also of Taylors
hypothesis, i.e., that our behavioral responses
are important to how we view a stimulus.
Intensity of the autonomic output arousal
does seem to differ between anxiety and
panic. Furthermore, panic attacks are fre-
quently accompanied by an intense desire to
flee/actual flight.
Padua Carobrez: Is anxiety a dysregula-
tion of the normal defense system? How
does panic fit into this?
Francisco Guimarªes: Padua, panic is a
normal defensive reaction. The big (and un-
solved) question is why some people tend to
develop spontaneous panic attacks?
Caroline & Robert Blanchard: Hi ev-
erybody! Were at home, with only one com-
puter so our names will appear together. Is
panic a big anxiety? Our response is no. Not
clinically, not in terms of drug response, and
certainly not in terms of animal models. We
think the difference is that they represent
exacerbation or abnormal functioning in two
different sets of defense systems, flight for
panic and risk assessment (and defensive
threat/attack) for a more general anxiety.
These are certainly not just our assumptions,
and it is interesting that other tasks used to
model panic and anxiety have generally been
successful in calling specific attention to
these particular behaviors.
Marcus Brandªo: I agree with the
Blanchards. I do not think that panic is a big
generalized anxiety. There are several dif-
ferences from the clinical viewpoint. Just to
mention one, anxiety is an adaptive response
with a slow onset while panic is sudden and
does not serve any adaptive function. Be-
sides there are some proposals, mainly Deakin
and Graeffs (2), drawn from animal models
of anxiety that consider them two distinct
processes.
Luiz Carlos Schenberg: Marcus, of
course panic is adaptive. Have you ever
faced an angry pit bull? This is physiological
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panic. Pathological panic (anxiety neurosis)
or anxiety are maladaptive, but not the physi-
ological expression of both states.
Caroline & Robert Blanchard: Schen-
berg asked an interesting question. Certainly
the autonomic components associated with
any high level defensive arousal will be use-
ful in facing an angry pit bull. Some defen-
sive behaviors will probably be more useful
than others (flight is probably poor in that
case). The question is what is useful and
when, and the degree to which psycho-
pathologies represent genuinely maladaptive
defense both now and in the evolution of
mammals.
Frederico Graeff: Recent results ob-
tained by Cristina M. Del Ben with panic
disorder patients in human models of anxi-
ety show that they have high baseline anxi-
ety, but normal levels of arousal (visual ana-
log mood scale mental sedation factor). Simu-
lated public speaking (seemingly related to
innate fear) does not enhance anxiety in
these patients or increase arousal. Yet they
behave like controls in the conditioned fear
test (skin conductance). These results are
compatible with the suggestion that in panic
patients high anxiety is inhibiting panic (2,3).
Luiz Carlos Schenberg: We have al-
most completed a study on a group showing
the reduction in defense reaction thresholds
(in the dorsal periaqueductal gray matter)
following dexamethasone administration. In
this case, anxiety should facilitate panic.
John Rodgers: Whether panic is simply
quantitatively different from generalized
anxiety disorder is still an issue, certainly for
clinicians (and as such, should also be so for
preclinical researchers/animal modelers). A
key line of evidence in favor of a qualita-
tively different phenomenon (leading to sepa-
rate classification in DSM) was of course the
apparently poor therapeutic response to ben-
zodiazepines and good therapeutic response
to monoamine oxidase inhibitors and tricy-
clics (and now also selective serotonin (5-
HT) reuptake inhibitors). However, antide-
pressants are also very effective (some say
more effective than benzodiazepines) in gen-
eralized anxiety disorder, while high doses
of the more potent benzodiazepines appar-
ently do work in panic. All of this might well
suggest that panic is indeed just a more
intense reaction than generalized anxiety dis-
order. However, one thing has always struck
me about panic vs generalized anxiety disor-
der - the former relates very much more to a
disturbance (catastrophic interpretation) in
the processing of internal physiological
stimuli while the latter appears to relate much
more to a general disturbance (hypervigi-
lance) in the processing of stimuli from the
external world. So, the dysfunction in each
case is not with respect to the defensive
reaction per se but with earlier stages of
information-processing (i.e., interpretation
of input as signifying danger/threat when it
is not - leading to inappropriate or exagger-
ated response?). As such, models focussing
on adaptive responses of normal animals to
an actual/potential threat (virtually all mod-
els) may be missing the point. This would
argue for the need to very carefully select
species and/or strains not only for high lev-
els of trait defensiveness (measured in di-
verse contexts) but also for the tendency to
display such responses to non-threatening as
well as threatening events.
Roberto Andreatini: I believe that panic
could be a big anxiety. The clear separation
between panic and generalized anxiety dis-
order proposed earlier is less clear today.
One important aspect of this separation was
the difference in the pharmacological treat-
ment of these disorders: tricyclic antidepres-
sants for panic and benzodiazepines for gen-
eralized anxiety disorder. However, recent
papers suggest that panic can be treated with
benzodiazepines (alprazolam and clonaze-
pam) and generalized anxiety disorder can
be treated with tricyclic antidepressants and
serotonin reuptake inhibitors (4).
Frederico Graeff: Roberto, there are
opposite results with ritanserin, an experi-
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mental 5-HT2 antagonist. Anxiety is relieved,
but panic is aggravated.
Francisco Guimarªes: The same could
be said about d-fenfluramine (5).
Sheila Handley: Buspirone is active in
generalized anxiety disorder but it has no
significant benefit in panic disorder.
Guy Griebel: I also believe that panic
may be a big anxiety attack. The alleviation
of panic symptoms usually requires high
doses of benzodiazepines which are very
effective at low doses against generalized
anxiety, perhaps a more moderate type of
anxiety disorder (6,7). However, panic may
also be something clearly different from gen-
eralized anxiety in that the mechanisms in-
volved seem to be different. While there is
little doubt that generalized anxiety involves
the GABA/benzodiazepine receptor com-
plex, panic involves (in addition?) other neu-
rotransmitters such as serotonin, noradrena-
line or even several neuropeptide systems
such as cholecystokinin.
Caroline & Robert Blanchard: Guy,
regarding your informative comment, are
you saying that benzodiazepines may be re-
garded as relatively selective antipanic com-
pounds, but only when given chronically at
high doses? Puts them right in with other
antipanic drugs. Are there any antipanic drugs
that work acutely?
Francisco Guimarªes: Robert and
Caroline, based on data from our public
speaking model we suggested that d-fenflur-
amine could act acutely. Dr. Luiz A. Hetem,
here in Brazil, treated successfully some pa-
tients with the drug before it was withdrawn
from the market.
Roberto Andreatini: I think that in clini-
cal settings the effect of benzodiazepines is
faster than that of antidepressive drugs in
reducing panic attacks (8,9).
Guy Griebel: Roberto, benzodiazepines
may be effective against panic after only a
few days of treatment, whereas antidepres-
sants, especially tricyclics, require several
weeks to show some reduction in the occur-
rence of panic frequency (9,10).
Roberto Andreatini: Yes, I agree with
you.
Frederico Graeff: Guy, although benzo-
diazepines are quicker to improve panic than
antidepressants, if you compare to general-
ized anxiety disorder it seems that you need
higher doses of potent compounds and sev-
eral days.
Guy Griebel: Yes, I agree with you.
Guy Griebel: Robert and Caroline, there
is a very rapid tolerance to the sedative ac-
tion of high doses of benzodiazepines fol-
lowing repeated treatment (11). This leaves
us, I believe, with a specific anxiolytic effect
(on panic) which shows no development of
tolerance.
Caroline & Robert Blanchard: Guy, I
take your point about the benzodiazepines,
but how specific is the benzodiazepine ef-
fect on panic. Really high benzodiazepine
doses will reduce just about anything!
Guy Griebel: Yes, some benzodiazepines
(alprazolam, clonazepam, diazepam, cloraze-
pate) are specific antipanic compounds after
repeated treatment with high doses (6). On a
clinical level, no drug (so far) works specif-
ically (i.e., without producing sedation)
against panic after a single administration.
Frederico Graeff: Luiz, I think one im-
portant difference between panic and anxi-
ety is that in the latter adrenocorticotropic
hormone (ACTH) is not released. I believe
you have data showing that electrical stimu-
lation of the dorsal periaqueductal gray mat-
ter does not activate the hypothalamus-pitu-
itary-adrenal axis. Am I right?
Luiz Carlos Schenberg: Yes, likewise
in panic attacks, neither ACTH nor plasma
prolactin levels showed any change follow-
ing 1 min full-blown freezing and flight be-
haviors. There seems to be an active inhibi-
tion of the hypothalamus-pituitary-adrenal
axis, because no one who experienced a
panic attack could say that it is not stress-
ing.
Francisco Guimarªes: This lack of
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ACTH increase is really puzzling. If I am not
wrong, the hippocampus exerts an inhibitory
influence on the paraventricular nucleus.
Could it be involved in this effect?
Sheila Handley: Frederico and Luiz - I
would like to put in a comment here. I won-
der what the baseline values were in your
experiments, Luiz? If patients or animals are
already stressed, important effects on circu-
lating corticosteroids can be obscured (see
Ref. 12). Also, prolonged elevation of circu-
lating corticosteroids is likely to down-regu-
late the receptors responsible for negative
feedback; this is one reason put forward for
the hypercortisolemia of depression but we
dont know if it occurs in anxiety disorders.
The literature on hypothalamus-pituitary-
adrenal axis activation in panic attacks is
inconsistent (see Refs. 13 and 14) and diffi-
culty of obtaining a satisfactory baseline in
panic-disorder patients could be a factor.
Nevertheless, acute increases in salivary cor-
tisol have been demonstrated recently dur-
ing spontaneous panic attacks (13). The cir-
cadian trough for circulating corticosteroids,
together with the threshold of the stress re-
sponse is thought to be controlled by miner-
alocorticoid receptors, probably in the hip-
pocampus, while glucocorticoid receptors
have been suggested to govern the extent and
duration of the stress-induced rise by con-
trolling the rate of return to baseline through
negative feedback (see Refs. 12 and 15). It
may be that all prevailing corticosteroid lev-
els above the circadian trough are actually
due to ongoing microstresses. We have
recently measured afternoon salivary corti-
sol in a familiar environment in children
with attention deficit hyperactivity disorder
and found significantly lower levels; we sug-
gest this could be because they are not pro-
cessing properly the environmental informa-
tion that would normally lead to a parallel
inhibition of behavior and activation of the
hypothalamus-pituitary-adrenal axis (16). On
a slightly different track, we knocked down
the glycocorticoid receptors with an anti-
sense oligonucleotide delivered icv in rats
and found a parallel increase in 5-HT2A
receptor expression accompanied by an in-
crease in 2,5-dimethoxy-4-iodoamphet-
amine-induced head-shakes (17). This illus-
trates the potential importance of the hypo-
thalamus-pituitary-adrenal axis in control-
ling 5-HT responsiveness but we havent yet
looked at the effect on anxiety.
Caroline & Robert Blanchard: Luiz,
what about autonomic changes in conjunc-
tion with lack of hypothalamus-pituitary-
adrenal axis arousal, in panic?
Luiz Carlos Schenberg: The autonomic
changes of dorsal periaqueductal gray mat-
ter-induced flight are quite similar to panic
attacks, shallow and fast respiration, tachy-
cardia and hypertension. The shallow fast
respiration is very important from a clinical
viewpoint.
Caroline & Robert Blanchard: I am
interested in the hypothalamus-pituitary-ad-
renal axis inhibition or shutdown of panic
because we are very consistently getting a
similar lack of hypothalamus-pituitary-adre-
nal axis response to acute stress in socially
stressed male rats. They dont, off hand,
look like panickers, but there could be some
sort of exhaustion effects since they (and
panickers) are certainly repeatedly aroused.
Do you have any information on the time
course of this hypothalamus-pituitary-adre-
nal axis inhibition?
Luiz Carlos Schenberg: Very important
results indeed! There are results in the litera-
ture, however, with the dominant-subordi-
nate paradigm, showing the opposite - in-
creased ACTH levels!
Caroline & Robert Blanchard: It may
be a matter of time and thresholds... In our
models we get this shutdown in both corti-
costerone and in paraventricular nucleus
corticotropic releasing factor expression, in
about 25 to 45% of subordinates, by about
12-14 days of grouping. No trace of this yet
in the other subordinates, and they tend to
have higher basal levels of corticosterone.
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Luiz Carlos Schenberg: The amygdala
seems to have another relationship with hy-
pothalamus-pituitary-adrenal axis.
Padua Carobrez: I dont know for sure
if panic is a big anxiety or something else.
For me the study of panic has to be divided
into two parts; an unconditioned (the panic
attack) component and a learned compo-
nent, that is able to keep the response going
on (contextual learning). In my opinion, a
reliable animal model for panic should be
able to include both parts.
Frederico Graeff: Marcus, I recall that
Daniel Viannas results in your lab showed
that electrolytic lesion of the ventrolateral
periaqueductal gray matter impaired freez-
ing generated by contextual fear condition-
ing, like in Fanselows original observations
(18). However, freezing induced by electri-
cal stimulation of the dorsal periaqueductal
gray matter remained unchanged. My guess
is that despite similar behavioral expression
(tense immobility) periaqueductal gray mat-
ter freezing relates to the complete immobil-
ity seen in panic attacks, in addition to flight.
Marcus Brandªo: You are right. Lesion
of the ventrolateral periaqueductal gray mat-
ter impaired contextual freezing, whereas
freezing from dorsal periaqueductal gray
matter stimulation was not affected by ven-
trolateral periaqueductal gray matter lesions.
I agree with you that probably dorsolateral
periaqueductal gray matter freezing may be
related to panic attacks.
Frederico Graeff: Luiz, both of you and
Francois Jenck work with stimulation of the
dorsal periaqueductal gray matter as a model
of panic (19). Are the results with panicolytic
and panicogenic drugs compatible?
Luiz Carlos Schenberg: In some sense,
yes. Fluoxetine selectively attenuated gal-
loping at low doses (1 mg kg-1 day-1, 21 days)
only, an important component of shuttle-box
escape in Jencks studies.
Francisco Guimarªes: Luiz, in the pre-
ceding chat on Emotion you told me that
acute clomipramine decreased defense
thresholds (with dorsal periaqueductal gray
matter stimulation). I think an important ques-
tion is what are the mechanisms of the initial
symptom worsening sometimes found with
selective serotonin reuptake inhibitors in the
treatment of panic. Could this involve a shut-
down of 5-HT neurons in the dorsal raphe
nucleus and a consequent decrease in 5-HT-
mediated periaqueductal gray matter inhibi-
tion? We have recently finished an investi-
gation studying Fos-like immunoreactivity
in stressed (by restraint) and non-stressed
rats after acute or chronic (21 days) adminis-
tration of fluoxetine. A single administration
of fluoxetine decreased Fos-like immunore-
activity in the dorsolateral periaqueductal
gray matter in stressed rats, but chronic treat-
ment increased it in both stressed and non-
stressed animals.
Luiz Carlos Schenberg: No Francisco,
clomipramine increased the thresholds with
chronic administration (10 mg kg-1 day-1, 21
days). More precisely, clomipramine in-
creased the thresholds of immobility, trot-
ting, galloping, jumping and micturition, but
not exophthalmus or defecation.
Frederico Graeff: Luiz, in the chat on
Emotions you suggested that the medial
and central amygdala may be involved in
innate and learned fear, respectively. Why?
Luiz Carlos Schenberg: I suggested that
the medial amygdala could be involved in
innate fear of aversive odors.
Claudio Da Cunha: It is interesting that
some innate fears, and also anxiety respond
well to benzodiazepines and the highest den-
sity of benzodiazepine receptors is in the
basolateral amygdala (20).
Frederico Graeff: Let us switch to 5-
HT. Telma Andrade and HØlio Zangrossi Jr.
got nice results showing that electrolytic
lesion of the median raphe nucleus impaired
both inhibitory avoidance (learned fear) and
one-way escape (unlearned fear) in the rat
elevated T-maze test. 5,7-DHT lesion im-
paired avoidance, but not escape. Microin-
jection of 8-OH-DPAT into the median raphe
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nucleus had the same effect as the neuro-
toxic lesion, which was prevented by local
administration of a 5-HT1A receptor an-
tagonist (WAY 100635). These results sug-
gest that 5-HT neurons of the median raphe
nucleus regulate learned fear, and non-sero-
tonergic neurons regulate innate fear.
Francisco Guimarªes: One important
point in relation to the role of 5-HT in panic
and a possible inhibition of periaqueductal
gray matter is what happens during a flight
reaction. Recently, Maione and colleagues
(21) showed that N-methyl-D-aspartate
(NMDA) injection into the periaqueductal
gray matter can decrease 5-HT concentra-
tion in this region, whereas bicuculline in-
creased it. To explain these results it is pro-
posed that GABAergic neurons in the peri-
aqueductal gray matter project to the dorsal
raphe nucleus. So, we may suppose that
during a proximal defense reaction glutama-
tergic input to the periaqueductal gray mat-
ter would command flight and, at the same
time, would decrease the inhibitory 5-HT
input. Could you comment on this possibil-
ity?
Frederico Graeff: These results are en-
lightening. We suggested a 5-HT inhibitory
input to the dorsal periaqueductal gray mat-
ter coming from the amygdala (22). These
results point to an alternative feedback mech-
anism.
Marcus Brandªo: What about moving
to the second point of our chat? What as-
pects of anxiety does an animal model of
anxiety model?
Francois Jenck: What aspects of anxi-
ety do animal models model? Basic state-
ments: 1) Animals, like humans, express
different kinds of fear/anxiety in response to
different environmental conditions (i.e., acute
vs chronic stress, spontaneous vs conditioned
responses, etc.). 2) Only restricted aspects of
human psychopathology can be explored and
simulated using animal models. As many
others, we propose that a few fundamental
rules need to be followed: 1) A complete
neurobiological evaluation of any anti-anxi-
ety effect requires that effects be examined
in several paradigms. 2) The continuum ex-
isting clinically between anxiety and depres-
sive disorders must be taken into consider-
ation. 3) The best animal models must be
evaluated and selected for their face validity,
predictive validity, and construct validity.
We have obtained pharmacological evidence
for preferentially relating some animal mod-
els to specific anxiety disorders in man. In
addition, many contradictions about the role
of neurotransmitter systems in anxiety can
probably be explained by their anatomical,
pharmacological and functional heterogene-
ity. Clinical and preclinical data are compat-
ible with the hypothesis that different neuro-
transmitters/modulators have distinct and
opposite roles in modulating different kinds
of anxiety in different brain regions. Deakin
and Graeff theory (2): The opposite patterns
of results observed with 5-HT receptor ago-
nists and antagonists in different models are
not mutually exclusive but rather suggest
that 5-HT receptor subtypes exert an elabo-
rate control over different types of anxiety.
For instance, 5-HT2C neurotransmission se-
lectively modulates specific kinds of anxiety
generated by different animal models (23).
This is in line with the Deakin and Graeff
theory (2) on the complex action of 5-HT on
the neural mechanism of anxiety where 5-
HT is hypothesized and found to either fa-
cilitate or inhibit different kinds of fear in
different brain regions. Different anxiety
states in animals or man probably recruit and
involve different brain regions and receptor
types, either alone or in combination, hence
with different symptomatic outcomes. In that
respect, the use of nonselective probes such
as m-CPP is likely to generate contaminated
results and cannot be applied to the elucida-
tion of the physiological machinery involved.
Guy Griebel: The easiest way to answer
this question is to look at the pharmacologi-
cal data obtained with anxiety models. Con-
flict models which are mostly sensitive to
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benzodiazepines, drugs used to treat gener-
alized anxiety, may probably only model
aspects of this condition. Tests that rely on
exploratory behaviors are much more com-
plex as they are sensitive to all kind of psy-
choactive drugs (some of them are not even
active against any anxiety disorder). This is
probably because different motivations can
lead to the same behavioral outcome in ex-
ploration models (i.e., an increase in time
spent in an aversive area). Factor analysis
has clearly shown that behaviors in explora-
tion models (notably the elevated plus-maze)
relate to different aspects of emotional pro-
cesses. Benzodiazepines are very effective
in these tests. As such, exploration tests
model predominantly certain aspects of gen-
eralized anxiety. Do exploration models also
model panic? I have some doubts, as 5-HT
reuptake inhibitors, which are the mainstay
of drug treatment in this condition, are gen-
erally not active in these tests. What about
phobias? The problem with this condition is
that there are not that many effective phar-
macological treatments.
Frederico Graeff: Guy, then, models of
phobia should be sensitive to exposure?
Guy Griebel: Im not sure about that,
Frederico. Phobias are more cognitive-ori-
ented anxiety disorders, which are very diffi-
cult to model in animals. To illustrate this
idea, propranolol, which is among the most
effective drug treatments against social pho-
bia, is inactive in all anxiety models (24).
Roberto Andreatini: Which phobia?
Social, agoraphobia, or simple phobia? So-
cial phobia has a moderate response to mono-
amine oxidase inhibitors (e.g., phenelzine).
On the other hand, simple phobia is unlikely
to show any improvement with pharmacolo-
gical treatment.
JosØ Roberto Leite: Frederico, if we
consider learned fear, exposure is a very
effective procedure. For instance, in passive
avoidance, where we exposed the animals to
the situation without punishment, the fear of
a dark place is quickly extinguished. In the
elevated plus-maze, on the other hand, expo-
sure to open arms is not effective to modify
the avoidance behavior of the open arm.
Claudio Da Cunha: In passive avoid-
ance, animals do not naturally fear the dark
compartment. They learn to fear it after the
shock. If the unconditioned stimulus (shock)
remains present they will continue to fear it.
Luiz Carlos Schenberg: Guy, may be
conditioned fear and unconditioned fear have
different pharmacological profiles, like anxi-
ety and panic. In our model, threshold logis-
tic analysis, fluoxetine inhibited galloping
only, but not the other dorsal periaqueductal
gray matter-induced defensive behavior.
Marcus Brandªo: Luiz, getting back to
the problem of physiological and pathologi-
cal panic. Considering that we work with
animal models, how can we clearly distin-
guish between them in animals? Can we
specify these conditions before conducting
any particular experiments?
Luiz Carlos Schenberg: No, we cant.
Frederico Graeff: Marcus, animals are
obviously not in panic in many animal mod-
els, like the defense test battery or escape in
the elevated T-maze. What may be claimed
is that we are dealing with mechanisms un-
derlying adaptive behavior that are supposed
to go wrong in panic disorder. In this respect,
Maria Cristina L. Silveira carried out a c-Fos
study in rats on the elevated T-maze. Perfor-
mance of the avoidance task (withdrawal
from the enclosed arm) increased Fos-like
immunoreactivity in the medial nucleus of
the amygdala, paraventricular nucleus of the
thalamus, anterior hypothalamic nucleus and
median raphe nucleus. In contrast, perfor-
mance of escape (from the open arm) en-
hanced Fos-like immunoreactivity in the dor-
sal periaqueductal gray matter. Both behav-
ioral tasks increased Fos-like immunoreac-
tivity in the dorsomedial nucleus of the hy-
pothalamus. Therefore, inhibitory avoidance
and one-way escape activated different sets
of brain structures, respectively. This evi-
dence supports the original hypothesis that
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two types of fear/anxiety are generated in the
elevated T-maze, learned and unlearned, re-
spectively.
Frederico Graeff: Guy, do you think we
have a good animal model of panic?
Guy Griebel: There are several models
that claim to model panic (dorsal periaque-
ductal gray matter stimulation, T-maze,
mouse defense test battery...), mainly based
on pharmacological data (25). My opinion is
that a model of panic is predictive of an
antipanic-like activity or may be considered
as reliable for modeling this condition if
different laboratories using the same model
have found similar results. That is not really
the case at the present time because nobody
is using the same panic test.
Sheila Handley: In animal models we
are only able to model the behavioral output.
I think we need a much tighter definition of
panic, otherwise we can make of it what we
like. For instance, is freezing a symptom of
panic or not? Freezing is very rare in humans
and it is not listed as a symptom of panic
disorder in DSM IV1 or ICD-102. On the
other hand, the desire to flee, or actual flight
(...an exit, usually hurried, from wherever he
or she may be (ICD-10)) are common in
human panic and can sometimes lead to
disastrous attempts to escape. On that basis,
the periaqueductal gray matter stimulation
and other models that elicit flight behavior
all have face-validity.
Caroline & Robert Blanchard: One way
might be through the use of agents that can
produce panic in people. Cocaine is working
very well in our rats, in eliciting a high level
panic-like flight response, which could then
be used in conjunction with other manipula-
tions. Havent used sodium lactate yet, but
plan to. Another approach (already under-
way) is to try to understand the biology of the
defense systems, with a second tactic of
trying to experimentally link specific aspects
of defense to particular defense-related psy-
chopathologies.
Frederico Graeff: JosØ Roberto, you
have worked on pentylenetetrazole and anxi-
ety. Pentylenetetrazole induces panic-like
states in humans. Before falling into fits, rats
run wildly - as if in panic - in the sound-
induced epilepsy model. Are panic and con-
vulsions related?
JosØ Roberto Leite: I believe that clonic
convulsions induced by pentylenetetrazole
could be a model for panic. If we consider
the descriptions of the behavioral effect in
humans this should be an interesting animal
model. We do not forget about the benzodi-
azepine specific antagonism of the effects of
pentylenetetrazole. If we consider the clini-
cal point of view, I think that this should be
a limitation of the model.
Padua Carobrez: Pentylenetetrazole (15
and 30 mg/kg)-induced anxiety, measured in
the plus-maze, disappeared after NMDA/
glycine antagonism into the dorsal periaque-
ductal gray matter (26).
Frederico Graeff: Sorry, but it is time to
end. I am thankful to Claudio Da Cunha for
organizing this chat, and to all participants. It
was very stimulating. Best wishes to every-
one.
Claudio Da Cunha: In the name of the
Brazilian Society of Neuroscience and Be-
havior I would like to thank you all and say
that it was a pleasure to be with you in this
chat.
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